Prostate Cancer Screening in Men With Germline BRCA2 Mutations
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Number of Prostate Cancer Patients With BRCA2 Mutation Carriers
研究概览
简要总结
The purpose of this study is to determine the incidence of prostate cancer in men with the BRCa2 gene mutation as an independent indicator for prostate cancer screening.
详细描述
This is a cohort screening study to prospectively identify the incidence of prostate cancer in a population of BRCA2 carriers. All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing.
Standard of care screening at the Yale Cancer Center for men with a normal prostate cancer risk consists of a PSA test and prostate physical examination beginning at age 50 years and if either is abnormal an MRI of the prostate followed by Fusion-targeted biopsy of the prostate is performed.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 90 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •All men ≥30 years of age with at least a ten-year life expectancy
- •A known BRCA2 mutation
- •Ability to have an MRI
- •Able to give informed consent will be approached to participate in the study
排除标准
- •If a man has received or is currently receiving treatment for prostate cancer
结局指标
主要结局
Number of Prostate Cancer Patients With BRCA2 Mutation Carriers
时间窗: Up to 3 years
number of patients with a BRCA2 mutation who are diagnosed with prostate cancer
次要结局
未报告次要终点